DelveInsight’s ‘Chronic Myelomonocytic Leukemia Pipeline Insight 2024’ report highlights the significant progress in the treatment of CMML, a rare blood cancer, with over 22 companies developing 25+ potential therapies. The report details key players, promising drugs like Tipifarnib and IO-202, and recent clinical trial updates.